CTRI/2022/07/044021尚未招募4 期
A Prospective, Post-market, Multi-center, Single-arm, Real-world Observational Registry to evaluate safety and performance of Dafodil™ Pericardial Bioprosthesis in patients who underwent replacement of their natural or prosthetic aortic or mitral valve. - DAWN (Dafodil pericArdial bioprosthesis real-World National registry
Meril Life Sciences Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •Inclusion Criteria:
- •1. Patients implanted with Dafodil™ Pericardial Bioprosthesis or with its subsequent advanced versions.
- •2. Patients or LAR (Legally Acceptable Representative) has given written informed consent for participation prior to enrolment.
- •3. Patient is willing to undergo all study procedures and follow-up requirements.
排除标准
- 未提供
研究者
相似试验
尚未招募
4 期
A clinical trial to assess the efficacy and safety of Formoterol fumarate and Fluticasone propionate powder for inhalation (Formoflo 250) in the patients withAsthmaCTRI/2023/08/056250upin Limited
尚未招募
不适用
Prospective, Multicenter, Post-market, Single Arm study to confirmthe performance of the RenzanTM Peripheral Stent System in treating Superficial Femoral and/or Popliteal artery diseasenarrowed leg arteriesperipheral disease10003216NL-OMON51143Terumo10
进行中（未招募）
1 期
A study to evaluate the risk of seizures among metastatic Castration-Resistant Prostate Cancer (mCRPC) patients treated with enzalutamideMedical condition: metastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 17.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003022-92-CZAstellas Pharma Global Development, Inc.424
进行中（未招募）
1 期
A study to evaluate the risk of seizures among metastatic Castration-Resistant Prostate Cancer (mCRPC) patients treated with enzalutamideMedical condition: metastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 18.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003022-92-BEAstellas Pharma Global Development, Inc.400
进行中（未招募）
1 期
A study to evaluate the risk of seizures among metastatic Castration-Resistant Prostate Cancer (mCRPC) patients treated with enzalutamideMedical condition: metastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 16.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003022-92-ESAstellas Pharma Global Development, Inc.400